Will Johnson & Johnson Stock Hit $300 This Year?
Johnson & Johnson (JNJ) stock has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a strong MedTech franchise. CEO Joaquin Duato highlighted a strong start to 2026, raising questions about whether the stock can hit $300.
Key Numbers
Johnson & Johnson (NYSE:JNJ) stock has rallied 13.73% year to date and 55.27% over the past year, driven by oncology blockbusters and a MedTech franchise firing on all cylinders. CEO Joaquin Duato told investors that "Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth." Analysts are now asking whether the stock can reach $300 this year.
Reasons for the Rally
The stock's strong performance is attributed to:
- Oncology drugs: Key products like Darzalex and Erbitux posted record sales.
- MedTech segment: Medical devices saw broad-based growth.
- Optimistic guidance: Duato expects accelerated growth in 2026.
Context
JNJ stock is trading near all-time highs, with a consensus analyst price target of $285. Some analysts believe reaching $300 is possible if momentum continues.
What This Means for Investors
Despite the strong performance, investors should watch for risks such as competition in oncology and regulatory challenges. Waraqty does not provide buy or sell recommendations.
Frequently Asked Questions
Found this useful? Share it